Heart failure, Hypertension
Conditions
Interventions
Experimental group1:S086 120mg
Experimental group2:S086 240mg
Experimental group3:S086 360mg
Experimental group4:LCZ696 200mg
Experimental group5:Losartan potassium150mg
Sponsors
The First Hospital of Jilin University
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1. Signed consent inform, acknowledge of content, procedure and potential adverse reactions of study; 2. Followed by study protocol and complete study; 3. Subjects (including their partners) have no pregnancy plan and voluntary to take effective contraceptive measures 4. Aged 18 to 55 years (including 18 and 55 years); 5. Body weight: Men >= 50kg, Women >=45kg, BMI=kg/m^2, 18-28 kg/m^2 (including 18-28 kg/m^2); 6. Normal hysical examination, vital sign or abnormal but no clinical significance ; 7. 90 mmHg<=SBP<140 mmHg, 60 mmHg<=DBP<90 mmHg.
Exclusion criteria
Exclusion criteria: 1. Average daily smoking >=5 cigarettes within 3 months before screening; 2. Known to have allergic reactions to angiotensin II receptor antagonists such as sacubitril, valsartan sodium, allisartan medoxomil, losartan, valsartan and the auxiliary materials of this product; or allergic physique (a variety of drugs and Food allergies); 3. A history of angioedema; 4. A history of orthostatic hypotension or syncope; 5. A history of alcohol abuse (drinking 14 units of alcohol per week: 1 unit = beer 285 mL, or spirits 25 mL , Or wine 100ml); 6. Positive urine drug screening or history of drug abuse or drug use in the past five years; 7. Blood donation or massive blood loss (> 450 mL) within 3 months before screening; 8. Before screening Take any drugs that change the activity of liver enzymes (CYP2C9, CYP3A4) or transporter (OAT1/3, OATP1B1/3, MRP2) inhibitors within 28 days; 9. Take any prescription drugs, over-the-counter drugs, or any vitamins within 14 days before screening Product or herbal medicine; 10. Take a special diet (including dragon fruit, mango, grapefruit, etc.) within 2 weeks before screening, or have strenuous exercise, or other factors that affect drug absorption, distribution, metabolism, and excretion; 11. Before screening 3 Have taken any research drug within a month; 12. Have a history of dysphagia or any gastrointestinal disease that affects the absorption of the drug; 13. Have any disease that increases the risk of bleeding, such as hemorrhoids, acute gastritis, or stomach and duodenum Ulcers, etc.; 14. 12-lead ECG abnormalities have clinical significance; 15. Female subjects in the screening period or during the trial Are breastfeeding or have a positive serum pregnancy result; 16. Clinical laboratory examinations have clinically significant abnormalities, or other clinical findings within 12 months before screening have shown clinical significance for the following diseases (including but not limited to gastrointestinal tract, kidney, Liver, nerve, blood, endocrine, tumor, lung, immune, mental or cardio-cerebrovascular disease); 17. Viral hepatitis (including hepatitis B and C), human immunodeficiency virus antibody, Treponema pallidum antibody screening positive; 18. Screening from Acute illness or concomitant medication from the stage to the study medication; 19. Chocolate, any caffeine-rich or xanthine-rich food or beverage 48 hours before taking the study medication; 20. Alcohol screening positive or taking the study medication Have taken any alcohol-containing products within the previous 48 hours; 21. Subjects who the investigator believes to have other factors that are not suitable for participating in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood pressure;cyclic guanosinc monophosphate;Amino Terminal b-type natriuretic peptide;Renin concentration;Renin activity;Angiotensinogen II;Aldosterone; | — |
Countries
China
Contacts
Public ContactYDing anhua
The First Hospital of Jilin University
Outcome results
None listed